Alistair McQueen, Head of Savings and Retirement at Aviva comments: "Today's figures show that ISA savers continue to be a risk-averse breed1.
"The 10.6% rise in ISA subscriptions in 2018/19 was driven by a bumper year for cash ISAs. Cash ISA subscriptions rose 20%, while stocks & shares ISA subscriptions fell 16%. Cash ISA subscriptions in 2018/19 represented 76% of all ISA subscriptions that year; up from 70% in the previous year.
"This love of cash comes despite the Bank of England setting historically low interest rates2. Many cash ISA savers will have actually achieved a negative rate of return last year as a result of inflation averaging above 2% in 2018/19, higher than the Bank of England's base rate. Meanwhile, stocks & shares ISAs, as measured by the FTSE 100, rose 3.7% over the same period.
"The Bank of England has projected a near trebling of the household savings ratio in 20203, partly the result of a sharp fall consumer spending as individuals look to build cash buffers to help mitigate the economic decline caused by the coronavirus crisis. The desire to save during times of uncertainty is understandable. All savers should ensure their savings are working as hard as possible; be that in bank accounts, ISAs, pensions, or elsewhere."
-Ends-
Sources:
1 https://www.gov.uk/government/statistics/individual-savings-account-statistics
2The Bank of England base rate rose from +0.5% to +0.75% In 2018/19
3 The Bank of England's latest Monetary Policy Report predicts household savings ratio to rise to 17% from 6%. The latest report can be found here: https://www.bankofengland.co.uk/-/media/boe/files/monetary-policy-report/2020/may/monetary-policy-report-may-2020
Media enquiries:
Fiona Whytock, 07800 692299
Notes to editors:
· For information on how Aviva is helping our people, customers and communities impacted by COVID-19 visit: www.aviva.com/covid-19-our-response/
· Aviva is a leading international savings, retirement and insurance business. We exist to be with people when it really matters, throughout their lives – to help them make the most of life. We have been taking care of people for more than 320 years, in line with our purpose of being 'with you today, for a better tomorrow'.
· Our vision is to earn our customers' trust as the best place to save for the future, navigate retirement and insure what matters most to them. In 2019, we paid £33.2 billion in claims and benefits on behalf of our 33.4 million customers.
· We operate through five business divisions: Investments, Savings & Retirement; UK Life; General Insurance; Europe Life; and Asia Life; and focus on three strategic priorities: deliver great customer outcomes, excel at the fundamentals and invest in sustainable growth.
· Total group assets under management at Aviva group are £510 billion and our Solvency II capital surplus is £12.6 billion (FY19). Our shares are listed on the London Stock Exchange and we are a member of the FTSE 100 index.
· For more details on what we do, our business and how we help our customers, visit www.aviva.com/about-us
· The Aviva newsroom at www.aviva.com/newsroom includes links to our image library, research reports and our news release archive. Sign up to get the latest news from Aviva by email.
· You can follow us on Twitter: www.twitter.com/avivaplc/
· You can follow us on LinkedIn: www.linkedin.com/company/aviva-plc
· For the latest corporate films from around our business, subscribe to our YouTube channel: www.youtube.com/user/aviva
· We have a Globelynx system for broadcast interviews. Please contact the Press Officer noted above if you would like to make a booking.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA